Dasiglucagon Demonstrates Reduced Costs in the Treatment of Severe Hypoglycemia in a Budget Impact Model

Jordan Hinahara and Thomas Goss, members of our Commercial Strategy and Market Access team, contributed to the budget impact model. The objective was to evaluate the economic impact of dasiglucagon compared with available glucagon treatments for SHE management, considering direct cost of treatment and health care resource utilization.

Meeting Early Phase Study Challenges – a Data Management Perspective

First-in-Human studies are a discovery point, which can decide the fate of a compound as well as lay the groundwork for subsequent phases of a...

Read More

Agile vs. Regulatory: How the Two Coexist and Contribute to Successful Medical Device Software Development

Software is gaining relevancy in a broad range of medical devices, as it either enables the control or influence of their operation, or because...

Read More
The Promise of Pulsed Field Ablation and the Critical Role of Preclinical Science in its Advancement

5 min read

The Promise of Pulsed Field Ablation and the Critical Role of Preclinical Science in its Advancement

CT Image of Pulmonary Veins Atrial fibrillation remains a leading cause of death and disability and the most common type of arrhythmia....

Read More